BioNet Provides Update on Recombinant Acellular Pertussis Vaccine at BioJapan 2014

General Press Releases Thursday October 16, 2014 12:12
YOKOHAMA, Japan--(BUSINESS WIRE)--Oct. 16, 2014
BioNet Recombinant Pertussis vaccine shows safety and immunogenicity in Phase I/II Clinical Study

BioNet-Asia's CEO, Dr Pham Hong Thai provided today an update on the company lead vaccine program in his presentation at BioJapan 2014. Dr Pham said that the current Phase I/II trial in Thailand showed that the vaccine is safe and immunogenic and full results will soon be published in a peer reviewed journal. BioNet Recombinant Acellular Pertussis vaccine will enter clinical Phase II/III in 2015.

Many licensed acellular pertussis vaccines have been associated to a resurgence of pertussis in developed countries. All these vaccines are inactivated by the use of chemicals which denature Pertussis Toxin, the principal antigen present in acellular vaccines. BioNet’s third-generation Pertussis vaccine is using a genetically-inactivated Pertussis Toxin which overcomes the limitations of the chemically-detoxified acellular vaccines. Hence, BioNet Recombinant Pertussis vaccine could potentially be the solution to the re-emergence of pertussis.

About Pertussis

Pertussis is a very contagious respiratory illness caused by Bordetella pertussis. Although the incidence of pertussis has declined through the routine immunization of children, vaccine-induced immunity does not persist long. This phenomenon of “waning immunity” was accentuated by the introduction of acellular pertussis vaccines. There are 16 million pertussis cases worldwide each year, mainly in adolescents and adults. These therefore pass on the disease to infants who have not yet completed their pertussis immunization series, and in whom pertussis is most severe. The resurgence of pertussis calls for the replacement of current acellular vaccines and for new vaccination strategies such as adult booster and maternal immunizations.

About BioNet-Asia

BioNet-Asia is an independent vaccine company with a focus on technological innovation and market access. BioNet has built several strategic alliances fostering vaccine self-reliance leading to the production and supply of billions of doses of vaccines worldwide. In its vaccine manufacturing plant in Thailand, BioNet is developing a broad pipeline of vaccines in R&D and clinical stages, such as Recombinant Acellular Pertussis, CRM197 protein carrier, Dengue and Hepatitis B vaccines. The company has transferred the technology to produce Hib meningitis vaccine which is now commercialized as a pentavalent vaccine in Asia. BioNet is a trusted vaccine partner for product development, technology transfer and global market access.

BioNet-Asia Co., Ltd.
Mr Supachai Nampornchaisakul, +66-2361-8110

Latest Press Release

Photo Release: Enrich Industrial (Thai) Inks Land Purchase Contract for New Plant at WHA Eastern Seaboard Industrial Estate 2

Enrich Industrial (Thai), a subsidiary of Vanguard Industrial (Jiaxing), global-scale manufacturer of high-end leather sofas, sofa beds and a broad range of seating facilities, recently signed a land purchase agreement with WHA Industrial Development for...

11.11 Singles day promotion at Siri Sathorn Hotel

Online shopping day on 11th November, originally celebrated by young Chinese singletons to indulge in online retail therapy, has evolved into one of the world's largest virtual sprees. With this in mind, Siri Sathorn Hotel is launching a gamification...

Breeze Cafe Bar introduces organic alternatives to get Beyond Delicious with 5 new menu items!

If you're bored with your daily healthy meals, come experience the new dimension of delicious organic recipes with five international menu items at Breeze Cafe & Bar, a chic restaurant and cafe at IMPACT Lakefront. The new options are specially...

Halloween Spooktacular at Cafe Kantary Get a 50% discount when you disguise yourself in ghostly costume!

On 24 – 31 October 2019, dare you join us at any branch of Cafe Kantary throughout Thailand for "Halloween Spooktacular"? For who know what surprises are waiting for you, lurking in the shadows? It's getting spooky and Cafe Kantary becomes a haunt...

Xinhua Silk Road: SAIC Motor gains momentum in India with 31,000 orders received by September

The Shanghai-based Chinese automaker SAIC Motor Corporation Limited (SAIC Motor, 600104.SH) is gaining momentum in India, with its production base opened in April this year and receiving 31,000 orders in three months after the launch of MG...

Related Topics